Navigation Links
Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
Date:3/10/2009

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has rescheduled its earnings call regarding its fourth quarter and year-end 2008 financial results, which was previously scheduled to be held on Thursday, March 12, 2009 at 8:30 a.m. Eastern Time, in order to complete its financial statement close and audit process. The Company will hold its conference call, issue a press release for the fourth quarter and year-ended December 31, 2008 and file its Annual Report on Form 10-K after market close on Monday, March 16, 2009.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the rescheduled call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, March 16.

To participate in the live call by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone-refractory) prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
2. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
3. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
6. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
7. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
8. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
9. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
10. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused ... for companion animals, will host a live conference call on ... financial results from the fourth quarter and full year ended ... may access the audio webcast or use the ... ...
(Date:2/22/2017)... , Feb. 22, 2017 Scientists propose in ... and organ damage in Gaucher and maybe other lysosomal ... and lower costs than current therapies. An ... Medical Center , which also included investigators from the ... report their data Feb. 22. The study was conducted ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... LabRoots ... and scientists from around the world, is pleased to announce the launch of a ... engineering and mathematics (STEM) fields. , This merit-based scholarship is open to all high ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the FDA CDRH ... Drug Evaluation Staff has joined the company as an Expert Consultant. , In ...
Breaking Biology Technology:
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
Breaking Biology News(10 mins):